Bank of America Merrill Lynch related stories
All articles and analysis
Merrill and TPG in co-investment talksThe US bank and the global buyout firm have held talks about the possibility of strengthening co-investment ties, after Merrill Lynch sounded out TPG last year on the possibility of receiving a capital injection from the buyout firm.
- KKR crescendo
For most of its 30 years in business, Kohlberg Kravis Roberts has been a dominant force in the private equity market. Following some intense introspection and retooling in the late 1990s, the New York-based firm is poised to again become the industry's heavyweight champion as it expands product lines, offices and head count around the world. David Snow takes a measure of the firm that invented, and reinvented, the big buyout.
- Merrill Lynch sells Debenhams stake
The private equity arm of the US bank has sold its remaining stake in the UK retail company, which has declined in value on the public markets, despite being the most lucrative UK buyout ever at the time of flotation.
- Blackstone faces class action suit
The alleged cover-up of poor performance at portfolio companies Freescale and FGIC are the main claims of the plaintiff, represented by a law firm that is filing a number of similar suits against major financial services firms.
- Silver Lake Sumeru hires Adobe exec
The mid-market arm of Silver Lake, currently in fundraising mode, has hired John Brennan to grow the group’s investment team.
- Biotech bang for buck(3)
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
- Biotech bang for buck(2)
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
- Biotech bang for buck
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
- Canadian court approves $52bn BCE buyout
A judge has dismissed a bondholders’ lawsuit critical to the success of the record-breaking BCE buyout by Ontario Teachers’, Madison Dearborn, Providence and Merrill Lynch.
- Global firms dominate the PEI Awards
In spite of the credit crunch, the global mega funds took centre stage in the Private Equity International Awards 2007. Mid-market resilience also found favour with voters in the only truly democratic private equity awards.